JAK inhibitors containing a 4-membered heterocyclic amide

US10392386B2 · kind B2 · utility

Assignee

• Theravance Biopharma R&D IP, LLC · US

Inventors

• Paul R. Fatheree · San Francisco, US
• Gary E. L. Brandt · Alameda, US
• Cameron Smith · Lawrenceville, US
• Steven D. E. Sullivan · San Francisco, US
• Lori Jean Van Orden · San Francisco, US
• Melanie A. Kleinschek · San Francisco, US
• Glenn D. Crater · Raleigh, US

Key dates

• Filing date: Dec 17, 2018
• Grant date: Aug 27, 2019
• Expiry date: Dec 17, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.